EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Optimizing third-line and beyond therapies for metastatic colorectal cancer in Taiwan: an evidence-based consensus

Pei-Hung Chang iD, Meng-Che Hsieh iD, Hao-Wei Teng, Yi-Hsin Liang, Hong-Hwa Chen, Hung-Chih Hsu iD, Jeng-Kai Jiang, Feng-Fan Chiang, Johnson Lin, Been-Ren Lin iD, Yao-Yu Hsieh, Tao-Wei Ke und 8 weitere

Therapeutic Advances in Medical Oncology · 2026-07 · 18

DOI: 10.1177/17588359261457553 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 08.07.2026. Verfasst von Pei-Hung Chang und 19 weiteren Autor:innen. Beteiligte Einrichtung: School of Traditional Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metastatic colorectal cancer (mCRC) is a major public health burden in Taiwan. Despite multiple later-line therapies, outcomes remain suboptimal. International guidelines provide valuable direction, but are difficult to apply locally due to differences in drug accessibility, reimbursement policies, and practice patterns.

Objectives

This initiative developed a Taiwan-specific, consensus framework for managing mCRC in the third line and beyond.

Design

This consensus integrated global evidence with local practice, real-world data, and reimbursement considerations.

Methods

A multidisciplinary panel of 20 experts convened by the Taiwan Society of Colon and Rectal Surgeons (TSCRS) used a modified Delphi process. Initial recommendations were adapted from European Society for Medical Oncology (ESMO), Pan-Asian ESMO, and National Comprehensive Cancer Network (NCCN) guidelines, supplemented by Taiwan real-world data. Consensus was achieved through three structured rounds of voting and discussion, with final statements graded by level of evidence and strength of agreement.

Results

Twelve recommendations spanning three domains were endorsed: disease management, third-line options, and extended strategies. Key local adaptations include aligning imaging schedule intervals with Taiwan’s National Health Insurance reimbursement policies and prioritizing trifluridine/tipiracil and regorafenib as preferred third-line agents. The panel acknowledged emerging options such as fruquintinib, epidermal growth factor receptor antibody rechallenge, and novel chemotherapy combinations. While the panel strongly supported biomarker-informed treatments, their broader implementation is constrained by limited reimbursement coverage for next-generation sequencing. Other challenges included limited drug access, suboptimal uptake of biomarker testing, and reimbursement constraints.

Conclusion

This Taiwan-specific consensus provides a practical, evidence-based framework for late-line mCRC treatment, bridging global standards with local realities to improve policy alignment and optimize patient outcomes.

Schlagwörter

Stichwörter der Autor:innen

Taiwanbiomarker-directed therapymetastatic colorectal cancerthird-line therapytrifluridine/tipiracil

Autor:innen und Institutionen

  • School of Traditional Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
  • Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Keelung, Taiwan.
  • Department of Hematology-Oncology, E-Da Cancer Hospital, Kaohsiung, Taiwan.
  • College of Medicine, I-Shou University, Kaohsiung, Taiwan.
  • Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.
  • School of Medicine, National Yang-Ming Chiao-Tung University, Taipei, Taiwan.

ORCID-Profile: Pei-Hung Chang, Meng-Che Hsieh, Hung-Chih Hsu, Been-Ren Lin, Jaw-Yuan Wang

Zitieren

APA

Chang, P. H., Hsieh, M. C., Teng, H. W., Liang, Y. H., Chen, H. H., Hsu, H. C., Jiang, J. K., Chiang, F. F., Lin, J., Lin, B. R., Hsieh, Y. Y., Ke, T. W., Kuan, F. C., Huang, W. S., Lin, B. W., Chang, Y. Y., Su, Y. L., Chen, W. T., Liu, C. K., & Wang, J. Y. (2026). Optimizing third-line and beyond therapies for metastatic colorectal cancer in Taiwan: an evidence-based consensus. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261457553

Vancouver

Chang PH, Hsieh MC, Teng HW, Liang YH, Chen HH, Hsu HC, et al. Optimizing third-line and beyond therapies for metastatic colorectal cancer in Taiwan: an evidence-based consensus. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261457553

BibTeX
@article{Chang2026,
  author = {Chang, Pei-Hung and Hsieh, Meng-Che and Teng, Hao-Wei and Liang, Yi-Hsin and Chen, Hong-Hwa and Hsu, Hung-Chih and Jiang, Jeng-Kai and Chiang, Feng-Fan and Lin, Johnson and Lin, Been-Ren and Hsieh, Yao-Yu and Ke, Tao-Wei and Kuan, Feng-Che and Huang, Wen-Shih and Lin, Bo-Wen and Chang, Yu-Yao and Su, Yu-Li and Chen, William Tzu-Liang and Liu, Chien-Kuo and Wang, Jaw-Yuan},
  title = {Optimizing third-line and beyond therapies for metastatic colorectal cancer in Taiwan: an evidence-based consensus},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2026},
  volume = {18},
  doi = {10.1177/17588359261457553}
}
Kostenlos starten →